Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Source: Eur Respir J 2009; 33: 387-393 Year: 2009
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012
Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017
First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017
Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1526-1527 Year: 2016
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1527-1529 Year: 2016
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021
The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2015; 45: 161-170 Year: 2015
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2016; 47:1591-1592 Year: 2016
Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2011; 38: 730-733 Year: 2011
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020